News & Updates

Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.

Patients with cirrhosis who have a history of depression are at greater risk of developing hepatic encephalopathy, reveals a study.

In patients with hepatocellular carcinoma (HCC), higher serum S-adenosylhomocysteine (SAH) concentrations may contribute to a shorter survival, regardless of the genetic variants of one-carbon metabolism key enzyme, according to a study.